 Jean Mulcahy Levy
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins B-raf | 8 | 2025 | 224 | 3.260 |
Why?
| | Brain Neoplasms | 15 | 2025 | 1238 | 2.630 |
Why?
| | Glioma | 10 | 2025 | 395 | 2.610 |
Why?
| | Autophagy | 8 | 2021 | 284 | 2.270 |
Why?
| | Central Nervous System Neoplasms | 3 | 2019 | 156 | 1.430 |
Why?
| | Ganglioglioma | 1 | 2025 | 35 | 0.930 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 674 | 0.700 |
Why?
| | Chloroquine | 3 | 2017 | 54 | 0.660 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 238 | 0.570 |
Why?
| | Mutation | 8 | 2025 | 3958 | 0.540 |
Why?
| | Chordoma | 1 | 2017 | 14 | 0.540 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 30 | 0.530 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 55 | 0.520 |
Why?
| | Indoles | 2 | 2017 | 412 | 0.500 |
Why?
| | Protein Kinase Inhibitors | 4 | 2025 | 916 | 0.490 |
Why?
| | Sulfonamides | 2 | 2017 | 513 | 0.480 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 801 | 0.480 |
Why?
| | Epilepsy | 1 | 2018 | 333 | 0.440 |
Why?
| | Neoplasms | 3 | 2025 | 2671 | 0.440 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 327 | 0.380 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 78 | 0.380 |
Why?
| | Antineoplastic Agents | 4 | 2017 | 2129 | 0.360 |
Why?
| | Ependymoma | 3 | 2019 | 165 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2017 | 622 | 0.350 |
Why?
| | Survivors | 2 | 2023 | 493 | 0.340 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1276 | 0.340 |
Why?
| | Child | 16 | 2025 | 21935 | 0.320 |
Why?
| | Child, Preschool | 10 | 2025 | 11074 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 215 | 0.300 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3412 | 0.270 |
Why?
| | Humans | 33 | 2025 | 137585 | 0.260 |
Why?
| | RNA-Binding Proteins | 2 | 2021 | 422 | 0.260 |
Why?
| | Cell Survival | 3 | 2019 | 1120 | 0.250 |
Why?
| | Cerebellar Neoplasms | 2 | 2018 | 152 | 0.240 |
Why?
| | Medulloblastoma | 2 | 2018 | 193 | 0.230 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2025 | 134 | 0.230 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2024 | 44 | 0.220 |
Why?
| | Astrocytoma | 1 | 2025 | 128 | 0.220 |
Why?
| | Adolescent | 10 | 2025 | 21513 | 0.220 |
Why?
| | Pyrimidinones | 1 | 2025 | 113 | 0.220 |
Why?
| | Retinal Diseases | 1 | 2025 | 91 | 0.220 |
Why?
| | Pyridones | 1 | 2025 | 168 | 0.210 |
Why?
| | Infant | 6 | 2025 | 9465 | 0.200 |
Why?
| | STAT3 Transcription Factor | 2 | 2015 | 206 | 0.200 |
Why?
| | Male | 16 | 2025 | 67762 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1050 | 0.190 |
Why?
| | raf Kinases | 1 | 2021 | 13 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.180 |
Why?
| | Transcriptome | 2 | 2025 | 971 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 48 | 0.180 |
Why?
| | Pituitary Diseases | 1 | 2020 | 20 | 0.170 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 37 | 0.170 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 16 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.160 |
Why?
| | Biological Assay | 2 | 2021 | 124 | 0.160 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 320 | 0.160 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2019 | 9 | 0.160 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2019 | 25 | 0.160 |
Why?
| | Aminopyridines | 1 | 2019 | 98 | 0.150 |
Why?
| | Multigene Family | 1 | 2019 | 198 | 0.150 |
Why?
| | Benzamides | 1 | 2019 | 216 | 0.150 |
Why?
| | Sepsis | 1 | 2025 | 617 | 0.150 |
Why?
| | Female | 13 | 2025 | 73304 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 77 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
| | Rhabdomyoma | 1 | 2017 | 8 | 0.140 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 31 | 0.140 |
Why?
| | Angiomyolipoma | 1 | 2017 | 24 | 0.140 |
Why?
| | Heart Neoplasms | 1 | 2017 | 50 | 0.130 |
Why?
| | Blotting, Western | 1 | 2019 | 1226 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 411 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2017 | 97 | 0.130 |
Why?
| | Mass Screening | 1 | 2025 | 1287 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2017 | 170 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 81 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.130 |
Why?
| | Drug Synergism | 1 | 2017 | 382 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 470 | 0.120 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 341 | 0.120 |
Why?
| | Flow Cytometry | 1 | 2019 | 1178 | 0.120 |
Why?
| | Outpatients | 1 | 2019 | 396 | 0.120 |
Why?
| | Apoptosis | 3 | 2019 | 2553 | 0.120 |
Why?
| | Prognosis | 3 | 2019 | 4030 | 0.120 |
Why?
| | Seizures | 1 | 2018 | 426 | 0.120 |
Why?
| | Signal Transduction | 2 | 2021 | 5079 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2019 | 956 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2017 | 2475 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 15657 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 658 | 0.110 |
Why?
| | Genetic Testing | 1 | 2017 | 460 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 327 | 0.110 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2014 | 39 | 0.110 |
Why?
| | Neuropsychological Tests | 2 | 2023 | 1023 | 0.110 |
Why?
| | NF-kappa B | 1 | 2017 | 691 | 0.100 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 692 | 0.100 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 403 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2017 | 712 | 0.100 |
Why?
| | Histones | 1 | 2018 | 636 | 0.100 |
Why?
| | Cohort Studies | 2 | 2021 | 5742 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2017 | 10811 | 0.090 |
Why?
| | Phenotype | 2 | 2024 | 3196 | 0.090 |
Why?
| | Glutamic Acid | 1 | 2014 | 246 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 202 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 778 | 0.090 |
Why?
| | Animals | 7 | 2025 | 36940 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2017 | 855 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 182 | 0.080 |
Why?
| | Hippocampus | 1 | 2014 | 895 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 496 | 0.070 |
Why?
| | Young Adult | 3 | 2021 | 13209 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1396 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7635 | 0.060 |
Why?
| | Adult | 2 | 2019 | 37929 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1236 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3566 | 0.060 |
Why?
| | Neurons | 1 | 2014 | 1590 | 0.060 |
Why?
| | Child, Hospitalized | 1 | 2025 | 49 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 978 | 0.060 |
Why?
| | Fluorescein Angiography | 1 | 2025 | 151 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2025 | 160 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2024 | 303 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 57 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2526 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 660 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 70 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 213 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2025 | 217 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1774 | 0.050 |
Why?
| | Visual Acuity | 1 | 2025 | 356 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.050 |
Why?
| | Autophagosomes | 1 | 2021 | 19 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 194 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
| | Lysosomes | 1 | 2021 | 141 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 911 | 0.040 |
Why?
| | Phosphorylation | 2 | 2015 | 1759 | 0.040 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2019 | 29 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 466 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 116 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 55 | 0.040 |
Why?
| | Aged | 1 | 2018 | 23961 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 190 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1062 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 166 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 155 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 377 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 327 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 305 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 17 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 48 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 643 | 0.030 |
Why?
| | Urea | 1 | 2016 | 81 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 601 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 201 | 0.030 |
Why?
| | Middle Aged | 1 | 2018 | 33479 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 378 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2199 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 85 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 13 | 0.030 |
Why?
| | Pepstatins | 1 | 2014 | 4 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 17 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2014 | 15 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 148 | 0.030 |
Why?
| | Leucine | 1 | 2014 | 111 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2069 | 0.030 |
Why?
| | Mice | 2 | 2025 | 17787 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 2014 | 107 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 188 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2014 | 143 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 6079 | 0.030 |
Why?
| | Pyrazoles | 1 | 2016 | 423 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 431 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1250 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2167 | 0.020 |
Why?
| | Tumor Burden | 1 | 2014 | 309 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 7604 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2014 | 196 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 563 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 698 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 513 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 362 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1783 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 622 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2014 | 844 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 465 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 872 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10388 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2426 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5131 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2607 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1692 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2085 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4193 | 0.020 |
Why?
| | Rats | 1 | 2014 | 5647 | 0.010 |
Why?
|
|
Mulcahy Levy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|